HOME >> MEDICINE >> NEWS
Earliest Warning Sign Indicates Need To Test For Condition Associated With Fetal Deaths

NEW ORLEANS -- Physicians traditionally have looked for the presence of at least three of several known clinical signs of chorioamnionitis before ordering a test for the condition, an inflammation of the fetal membranes that is a risk factor for fetal death.

Researchers at the University at Buffalo are recommending that the presence of only one of the known clinical signs is sufficient reason to conduct a diagnostic test for the condition, which they found present in nearly one-third of perinatal deaths recorded at a regional perinatal center during an eight-year period.

Results of the research were reported here today (May 11, 1998) by Lawrence J. Gugino, M.D., UB associate professor of gynecology and obstetrics and lead author, at the 46th annual clinical meeting of the American College of Obstetricians and Gynecologists.

Chorioamnionitis is associated with premature rupture of the fetal membrane and premature delivery. Both are independent risk factors for fetal death.

Gugino and colleagues reviewed the records of 804 perinatal deaths that occurred in Children's Hospital of Buffalo, a regional perinatal center, between 1988 and 1996. Chorioamnionitis was found to be present in 243, or about one-third of these cases, as determined by analysis of placental tissue.

Perinatal deaths include those that occur in utero and up to a month after birth. Traditionally, at least three of several possible clinical indicators -- including maternal fever, elevated white cell count, uterine tenderness, foul-smelling discharge and increased fetal heartbeat -- were considered necessary to justify screening for chorioamnionitis, Gugino said.

By comparing patient records during the pregnancy with results of the laboratory analysis of placental tissue after the fetal or infant death, Gugino and colleagues found that if only one of these symptoms is present, chorioamnionitis should be suspected and patients should be
'"/>

Contact: Lois Baker
baker@newsb.buffalo.edu
716-645-2626
University at Buffalo
11-May-1998


Page: 1 2

Related medicine news :

1. New Clinical Data Indicates LEUKINE Maintains Viral Suppression And Extends Duration Of Antiretroviral Therapy Utility In People With AIDS
2. Study Indicates That Medicare Costs Are Higher -- And Survival Rate Is Better --At Major Teaching Hospitals Survive Climate Change
3. Infants To Seniors: Seven Years Follow-Up Of 1,000 Liver Transplant Patients Taking Tacrolimus Indicates Children Have Best Survival
4. New Study Indicates Lightning Can Kill Without Leaving a Mark
5. UI Researchers Identify Possible Reason For Rare, Accelerated Aging Condition
6. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
7. Do Neurons Learn By Growing Thorns? Emergence Of Dendritic Spines Is Associated With Long-Term Synaptic Plasticity
8. Duke Researchers Identify New Pulmonary Syndrome Associated With Bone Marrow Transplantation For Breast Cancer
9. Fetal tissue restores lost sight
10. Fetal heart monitoring ineffective at diagnosing cerebral palsy
11. Fetal surgery for spina bifida shows early benefits in leg function, fewer shunts

Post Your Comments:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...
(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
(Date:5/21/2013)... May 21, 2013 Arizona State ... who want to develop their ideas into solutions, ... , The university is recruiting participants for ... “formation space” that provides early-stage entrepreneurs with opportunities ... is open to anyone, ASU is particularly seeking ...
(Date:5/21/2013)... 2013 The federal judge overseeing the ... lawsuits in U.S. District Court, Northern District of ... request from Plaintiffs’ Counsel to conduct Ex Parte interviews ... 17th Order grants that request, and sets forth procedures ... Wright Medical Technology, Inc., Conserve Hip Implant Products Liability ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: